Compare Redwire Corporation (RDW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Redwire Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? Redwire Corporation trades at $8.22 (market cap $2.15B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.4× Redwire Corporation's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Redwire Corporation for 18 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| RDW | SYRE | |
|---|---|---|
Market Cap | $2.15B | $7.35B |
Volume | 12,294,541 | 1,624,631 |
Sector | Industrials | Health |
52-Week High | $25.90 | $108.92 |
52-Week Low | $5.06 | $22.18 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $1.69B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Redwire (RDW) trades at $9.16, down 0.65% on the day, with a bearish technical outlook despite oversold RSI readings. The company shows strong revenue growth with 89.6% YoY increase in Q2 2026 but faces significant profitability challenges with a -57.26% net income margin. Recent developments include a $980 million Space Force contract win and partnerships with Honda and Sophia Space for robotics and orbital data center technology.
While analyst consensus remains strongly bullish with 80% buy ratings and a $14.88 price target, the stock faces substantial execution risks amid negative cash flow and dependence on SpaceX's Starship program. The combination of high growth potential and persistent losses creates a speculative investment case requiring careful risk assessment.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
